{
    "info": {
        "nct_id": "NCT03093116",
        "official_title": "A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)",
        "inclusion_criteria": "1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.\n2. ECOG PS 0-1.\n3. Age ≥18 (or age ≥ 20 of age as required by local regulation).\n4. Capability to swallow capsules intact (without chewing, crushing, or opening).\n5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.\n6. Prior cytotoxic chemotherapy is allowed.\n7. Prior immunotherapy is allowed.\n8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.\n9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.\n10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation\n11. Life expectancy ≥ 3 months.\n\nPHASE 2 Key Inclusion Criteria\n\n1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.\n2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:\n\n   1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.\n\n      • Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.\n\n      OR\n   2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.\n\n      * Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.\n3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.\n4. Age ≥12 (or age ≥ 20 as required by local regulation).\n5. Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.\n6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.\n7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.\n\n   i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors\n8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.\n9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation\n10. Life expectancy ≥ 3 months.\n\nKey Exclusion Criteria PHASE 1 and PHASE 2\n\n1. Concurrent participation in another therapeutic clinical trial.\n2. Symptomatic brain metastases or leptomeningeal involvement.\n3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.\n4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry\n5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2\n6. Any of the following cardiac criteria:\n\n   Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.\n7. Known active infections (bacterial, fungal, viral including HIV positivity).\n8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.\n9. Peripheral neuropathy of CTCAE ≥grade 2.\n10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": "PHASE 1\n\nKey"
    },
    "inclusion_lines": [
        {
            "line": "2. ECOG PS 0-1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG PS 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Capability to swallow capsules intact (without chewing, crushing, or opening).",
            "criterions": [
                {
                    "exact_snippets": "Capability to swallow capsules intact (without chewing, crushing, or opening)",
                    "criterion": "ability to swallow capsules intact",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method of ingestion",
                            "expected_value": "without chewing, crushing, or opening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Age ≥18 (or age ≥ 20 of age as required by local regulation).",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 (or age ≥ 20 of age as required by local regulation)",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "minimum value (local regulation)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7)",
                    "criterion": "tumor stage and type",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "Stage IV"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "locally advanced solid tumor",
                                "metastatic solid tumor",
                                "primary CNS tumor"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests",
                    "criterion": "gene rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "ALK gene rearrangement",
                                "ROS1 gene rearrangement",
                                "NTRK1 gene rearrangement",
                                "NTRK2 gene rearrangement",
                                "NTRK3 gene rearrangement"
                            ]
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "protocol specified tests"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 measurable target lesion according to RECIST version 1.1",
                    "criterion": "measurable target lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST version 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS-only measurable disease as defined by RECIST version 1.1 is allowed",
                    "criterion": "CNS-only measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST version 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Prior cytotoxic chemotherapy is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Prior cytotoxic chemotherapy is allowed.",
                    "criterion": "prior cytotoxic chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Prior immunotherapy is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Prior immunotherapy is allowed.",
                    "criterion": "prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.",
            "criterions": [
                {
                    "exact_snippets": "Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1",
                    "criterion": "acute toxic effects of prior anti-cancer therapy (excluding alopecia)",
                    "requirements": [
                        {
                            "requirement_type": "severity (NCI CTCAE v4.03 Grade)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.",
            "criterions": [
                {
                    "exact_snippets": "Patients with asymptomatic CNS metastases (treated or untreated) ... are eligible to enroll",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "asymptomatic leptomeningeal carcinomatosis are eligible to enroll",
                    "criterion": "leptomeningeal carcinomatosis",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Life expectancy ≥ 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced, or metastatic solid tumor (including primary CNS tumors)",
                    "criterion": "tumor stage and type",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "solid tumor",
                                "primary CNS tumor"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "harbors a ROS1, or NTRK1-3 gene fusion",
                    "criterion": "gene fusion status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "ROS1 gene fusion",
                                "NTRK1 gene fusion",
                                "NTRK2 gene fusion",
                                "NTRK3 gene fusion"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "• Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.",
            "criterions": [
                {
                    "exact_snippets": "Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory",
                    "criterion": "tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sent to central diagnostic laboratory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor",
                    "criterion": "central diagnostic laboratory test confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:",
            "criterions": [
                {
                    "exact_snippets": "documented ROS1 or NTRK1-3 gene fusion",
                    "criterion": "ROS1 or NTRK1-3 gene fusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by tissue-based local testing",
                    "criterion": "gene fusion determination method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "tissue-based local testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.",
            "criterions": [
                {
                    "exact_snippets": "a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility",
                    "criterion": "molecular eligibility",
                    "requirements": [
                        {
                            "requirement_type": "determination_method",
                            "expected_value": [
                                "next-generation sequencing (NGS)",
                                "quantitative polymerase chain reaction (qPCR)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.",
            "criterions": [
                {
                    "exact_snippets": "a fluorescence in situ hybridization (FISH) test ... will be accepted to determine molecular eligibility",
                    "criterion": "FISH test",
                    "requirements": [
                        {
                            "requirement_type": "performance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility",
                    "criterion": "fusion status confirmation by central diagnostic laboratory test",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory",
                    "criterion": "tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sent to central diagnostic laboratory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment",
                    "criterion": "central diagnostic laboratory test confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Age ≥12 (or age ≥ 20 as required by local regulation).",
            "criterions": [
                {
                    "exact_snippets": "Age ≥12 (or age ≥ 20 as required by local regulation)",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "minimum value (alternative, as required by local regulation)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 20,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.",
            "criterions": [
                {
                    "exact_snippets": "advanced solid tumors",
                    "criterion": "solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement",
                    "criterion": "gene rearrangement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "ROS1",
                                "NTRK1",
                                "NTRK2",
                                "NTRK3"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.",
            "criterions": [
                {
                    "exact_snippets": "Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation type",
                            "expected_value": "written IRB/institutional ethics committee-approved Informed Consent"
                        }
                    ]
                },
                {
                    "exact_snippets": "Assent signed by a parent or legal guardian for subjects age 12 to 17",
                    "criterion": "assent for minors (age 12 to 17)",
                    "requirements": [
                        {
                            "requirement_type": "documentation type",
                            "expected_value": "assent signed by a parent or legal guardian"
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 17,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Life expectancy ≥ 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy ≥ 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.",
            "criterions": [
                {
                    "exact_snippets": "Subjects with asymptomatic CNS metastases (treated or untreated)",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "asymptomatic leptomeningeal carcinomatosis",
                    "criterion": "leptomeningeal carcinomatosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "asymptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Symptomatic brain metastases or leptomeningeal involvement.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal involvement",
                    "criterion": "leptomeningeal involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors",
            "criterions": [
                {
                    "exact_snippets": "EXP-1: ROS1 TKI-naïve ROS1+ NSCLC",
                    "criterion": "NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "ROS1 fusion status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "ROS1 TKI treatment history",
                            "expected_value": "naïve"
                        }
                    ]
                },
                {
                    "exact_snippets": "EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC",
                    "criterion": "NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "ROS1 fusion status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "ROS1 TKI treatment history",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "prior ROS1 TKI"
                            }
                        },
                        {
                            "requirement_type": "platinum-based chemotherapy history",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "prior platinum-based chemotherapy"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)",
                    "criterion": "NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "ROS1 fusion status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "ROS1 TKI treatment history",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "prior ROS1 TKIs"
                            }
                        },
                        {
                            "requirement_type": "chemotherapy history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "immunotherapy history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)",
                    "criterion": "NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "ROS1 fusion status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "ROS1 TKI treatment history",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "prior ROS1 TKI"
                            }
                        },
                        {
                            "requirement_type": "chemotherapy history",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "immunotherapy history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "EXP-5: TRK TKI-naïve NTRK+ solid tumors",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "NTRK fusion status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "TRK TKI treatment history",
                            "expected_value": "naïve"
                        }
                    ]
                },
                {
                    "exact_snippets": "EXP-6: TRK TKI-pretreated NTRK+ solid tumors",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "NTRK fusion status",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "TRK TKI treatment history",
                            "expected_value": "pretreated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key Exclusion Criteria PHASE 1 and PHASE 2",
            "criterions": [
                {
                    "exact_snippets": "Key Exclusion Criteria PHASE 1 and PHASE 2",
                    "criterion": "exclusion criteria for PHASE 1 and PHASE 2",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Concurrent participation in another therapeutic clinical trial.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent participation in another therapeutic clinical trial.",
                    "criterion": "participation in another therapeutic clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "concurrent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Any of the following cardiac criteria:",
            "criterions": [
                {
                    "exact_snippets": "Any of the following cardiac criteria",
                    "criterion": "cardiac criteria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.",
            "criterions": [
                {
                    "exact_snippets": "History of previous cancer",
                    "criterion": "history of previous cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected",
                    "criterion": "type of previous cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "squamous cell carcinoma of the skin",
                                "basal-cell carcinoma of the skin",
                                "in situ carcinoma that has been completely resected"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring therapy within the previous 2 years",
                    "criterion": "previous cancer therapy timing",
                    "requirements": [
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Known active infections (bacterial, fungal, viral including HIV positivity).",
            "criterions": [
                {
                    "exact_snippets": "Known active infections (bacterial, fungal, viral including HIV positivity)",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "fungal",
                                "viral"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV positivity",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.",
            "criterions": [
                {
                    "exact_snippets": "At least 1 measurable target lesion according to RECIST (v1.1)",
                    "criterion": "measurable target lesion (per RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prospectively confirmed by Blinded Independent Central Radiology Review (BICR)",
                    "criterion": "confirmation of measurable target lesion by BICR",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "prospective confirmation by BICR"
                        }
                    ]
                },
                {
                    "exact_snippets": "selected by Sponsor, PRIOR to enrollment",
                    "criterion": "selection of target lesion by Sponsor prior to enrollment",
                    "requirements": [
                        {
                            "requirement_type": "selection",
                            "expected_value": "by Sponsor"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible",
                    "criterion": "CNS-only measurable disease (per RECIST v1.1)",
                    "requirements": [
                        {
                            "requirement_type": "location",
                            "expected_value": "CNS-only"
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.",
            "criterions": [
                {
                    "exact_snippets": "Mean resting corrected QT interval ... (QTcF) > 470 msec",
                    "criterion": "corrected QT interval (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "mean value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec)",
                    "criterion": "resting ECG",
                    "requirements": [
                        {
                            "requirement_type": "abnormalities in rhythm",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abnormalities in conduction",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abnormalities in morphology",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "PR interval > 250 msec",
                    "criterion": "PR interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 250,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.",
                    "criterion": "risk factors for QTc prolongation or arrhythmic events",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "heart failure",
                                "hypokalemia",
                                "congenital long QT syndrome",
                                "family history of long QT syndrome",
                                "concomitant medication known to prolong the QT interval"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of start of repotrectinib treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry",
                    "criterion": "radiation therapy (except palliative to relieve bone pain)",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry",
                    "criterion": "palliative radiation (≤10 fractions)",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure completion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 48,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Peripheral neuropathy of CTCAE ≥grade 2.",
            "criterions": [
                {
                    "exact_snippets": "Peripheral neuropathy of CTCAE ≥grade 2",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome)",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "Crohn's disease",
                                "ulcerative colitis",
                                "short gut syndrome"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "other malabsorption syndromes that would impact drug absorption",
                    "criterion": "malabsorption syndromes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "impact on drug absorption",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment)",
                    "criterion": "clinically significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary/peripheral artery bypass graft",
                    "criterion": "coronary artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "coronary/peripheral artery bypass graft",
                    "criterion": "peripheral artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II)",
                    "criterion": "symptomatic congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident or transient ischemic attack",
                    "criterion": "cerebrovascular accident",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular accident or transient ischemic attack",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic bradycardia",
                    "criterion": "symptomatic bradycardia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requirement for anti-arrhythmic medication",
                    "criterion": "requirement for anti-arrhythmic medication",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2",
                    "criterion": "ongoing cardiac dysrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "NCI CTCAE grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NCI CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [
        {
            "line": "PHASE 1",
            "criterions": [
                {
                    "exact_snippets": "PHASE 1",
                    "criterion": "trial phase",
                    "requirements": [
                        {
                            "requirement_type": "phase",
                            "expected_value": "1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [
        {
            "line": "PHASE 2 Key Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 10^9/L)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelets (PLTs) ≥100,000/mm3 (100 × 10^9/L)",
                    "criterion": "platelet count (PLTs)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hemoglobin ≥ 9.0 g/dL transfusions are allowed",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "transfusions allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min",
                    "criterion": "serum creatinine or creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal limits"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Total serum bilirubin < 1.5 × ULN",
                    "criterion": "total serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present",
                    "criterion": "liver transaminases (ASTs/ALTs)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity with liver metastases",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present",
                    "criterion": "alkaline phosphatase (ALP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity with liver and/or bone metastasis",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation",
                    "criterion": "serum calcium, magnesium, and potassium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": [
                                "normal",
                                "CTCAE grade ≤ 1"
                            ]
                        },
                        {
                            "requirement_type": "supplementation allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "OR",
            "criterions": []
        },
        {
            "line": "9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 10^9/L)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Platelets (PLTs) ≥100,000/mm3 (100 × 10^9/L)",
                    "criterion": "platelet count (PLTs)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Hemoglobin ≥ 9.0 g/dL transfusions are allowed",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "transfusions allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum creatinine or creatinine clearance > 40 mL/min",
                    "criterion": "serum creatinine or creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Total serum bilirubin < 1.5 × ULN",
                    "criterion": "total serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present",
                    "criterion": "liver transaminases (ASTs/ALTs)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity with liver metastases",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present",
                    "criterion": "alkaline phosphatase (ALP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "quantity with liver and/or bone metastasis",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation",
                    "criterion": "serum calcium, magnesium, and potassium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": [
                                "normal",
                                "CTCAE grade ≤ 1"
                            ]
                        },
                        {
                            "requirement_type": "supplementation allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.",
            "criterions": [
                {
                    "exact_snippets": "History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease",
                    "criterion": "interstitial fibrosis or interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "extent",
                            "expected_value": [
                                "extensive",
                                "disseminated",
                                "bilateral"
                            ]
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of hypersensitivity pneumonitis",
                    "criterion": "hypersensitivity pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of interstitial pneumonia",
                    "criterion": "interstitial pneumonia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of obliterative bronchiolitis",
                    "criterion": "obliterative bronchiolitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}